Search -

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

Presentation TCT 2019

ORSIRO: An “Ultra-Thin Strut” Metallic DES With Bioresorbable Polymer

Presenter: George Dangas

September 28, 2019

Presentation TCT 2019

Ultrathin Orsiro: Where It Can Go

Presenter: Steven Yakubov

September 26, 2019

Presentation TCT 2019

A Personal Perspective: Why I Choose Orsiro in STEMI

Presenter: Juan Fernando Iglesias

September 26, 2019

Presentation TCT 2019

First Experience With FDA-Approved Orsiro in the USA

Presenter: Farouc Jaffer

September 26, 2019

Presentation TCT 2019

Delivering Evidence

Presenter: James Hermiller

September 26, 2019

Presentation TCT 2019

TCT 43: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects with up to two de novo Coronary Artery Lesions – BIOFLOW IV: 4 Years Clinical Results

Presenter: Bernhard Witzenbichler

September 25, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Conference News EuroPCR 2019

Drug-Coated Balloons in STEMI ‘Safe and Feasible’ in Specific Circumstances: REVELATION

L.A. McKeown

May 22, 2019

News Conference News EuroPCR 2019

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

Caitlin E. Cox

May 21, 2019

News Industry News

BIOTRONIK Launches PK Papyrus Covered Coronary Stent in the US

April 10, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for February 2019

Shelley Wood

March 01, 2019

News Daily News

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Michael O'Riordan

February 22, 2019

Partner Content

Ultrathin Orsiro DES: Novel technology, eye-catching cases and robust evidence

March 7, 2019

Advertisement

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

ORSIRO: An “Ultra-Thin Strut” Metallic DES With Bioresorbable Polymer

Ultrathin Orsiro: Where It Can Go

A Personal Perspective: Why I Choose Orsiro in STEMI

First Experience With FDA-Approved Orsiro in the USA

Delivering Evidence

TCT 43: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects with up to two de novo Coronary Artery Lesions – BIOFLOW IV: 4 Years Clinical Results

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Drug-Coated Balloons in STEMI ‘Safe and Feasible’ in Specific Circumstances: REVELATION

Ultrathin Struts Show Strength in Small Vessels: BIO-RESORT at 3 Years

BIOTRONIK Launches PK Papyrus Covered Coronary Stent in the US

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

TCTMD’s Top 10 Most Popular Stories for February 2019

FDA Approves Orsiro Ultrathin-Strut Stent for CAD

Ultrathin Orsiro DES: Novel technology, eye-catching cases and robust evidence

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content